OXFORD IMMUNOTEC GLOBAL PLC 2,500,000 Ordinary Shares Underwriting AgreementOxford Immunotec Global PLC • August 18th, 2017 • In vitro & in vivo diagnostic substances • New York
Company FiledAugust 18th, 2017 Industry JurisdictionOxford Immunotec Global PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 2,500,000 ordinary shares, £0.006705 nominal value per share, of the Company (the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 375,000 ordinary shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The ordinary shares of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Ordinary Shares.” To the extent there are no additional Underwriters listed on Schedule I other than you, the terms Representative and Underwriters shall, mutatis mutandis, be deemed to refer to you.
OXFORD IMMUNOTEC GLOBAL PLC [•] Ordinary Shares Underwriting AgreementUnderwriting Agreement • November 14th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
Contract Type FiledNovember 14th, 2013 Company Industry JurisdictionOxford Immunotec Global PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] ordinary shares, £0.006705 nominal value per share, of the Company (the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional [•] ordinary shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The ordinary shares of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Ordinary Shares.”
OXFORD IMMUNOTEC, INC. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • North Carolina
Contract Type FiledOctober 15th, 2013 Company Industry JurisdictionThis LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of May 24, 2013, by and between Square 1 Bank (“Bank”) and Oxford Immunotec, Inc. (“Borrower”).
OXFORD IMMUNOTEC GLOBAL PLC 4,255,319 Ordinary Shares Underwriting AgreementLetter Agreement • February 4th, 2015 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
Contract Type FiledFebruary 4th, 2015 Company Industry JurisdictionOxford Immunotec Global PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 4,255,319 ordinary shares, £0.006705 nominal value per share, of the Company (the “Underwritten Shares”). In addition, solely for the purpose of covering overallotments, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 638,297 ordinary shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The ordinary shares of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Ordinary Shares.”
CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) dated as of October 4, 2016 by and among OXFORD IMMUNOTEC, INC., as Borrower, OXFORD IMMUNOTEC GLOBAL PLC and OXFORD IMMUNOTEC LIMITED, as guarantors, the other Credit Parties party from time to...Credit, Security and Guaranty Agreement • October 7th, 2016 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
Contract Type FiledOctober 7th, 2016 Company Industry JurisdictionTHIS CREDIT, SECURITY AND GUARANTY AGREEMENT (REVOLVING LOAN) (as the same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”) is dated as of October 4, 2016 by and among Oxford immunotec, inc., a Delaware corporation, and any additional borrower that may hereafter be added to this Agreement (individually as a “Borrower”, and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the “Borrowers”), OXFORD IMMUNOTEC GLOBAL PLC, a company formed under the laws of England and Wales (“Oxford Global”), OXFORD IMMUNOTEC LIMITED, a company formed under the laws of England and Wales (“Oxford Limited” and together with Oxford Global and any other entities that become party hereto as a Guarantor and each of their successors and permitted assigns, individually as a “Guarantor” and collectively, as the “Guarantors”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, individually as a Lend
OXFORD IMMUNOTEC GLOBAL PLC $40,000,000 ORDINARY SHARES SALES AGREEMENTSales Agreement • December 21st, 2016 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
Contract Type FiledDecember 21st, 2016 Company Industry JurisdictionOxford Immunotec Global PLC (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Dated 8 August 2007 MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED and OXFORD IMMUNOTEC LIMITED Counterpart LEASE of Unit 94C Milton ParkOxford Immunotec Global PLC • October 15th, 2013 • In vitro & in vivo diagnostic substances
Company FiledOctober 15th, 2013 Industry
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2020 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • Massachusetts
Contract Type FiledMarch 6th, 2020 Company Industry JurisdictionThis Employment Agreement (the "Agreement") is made and entered into effective as of this 28th day of August, 2017 (the "Effective Date") by and between Oxford lmmunotec, Inc., a Delaware corporation with a usual place of business at 700 Nickerson Road, Suite 200, Marlborough, MA 01752 (the "Company") and Stefan Linn (the "Employee").
OFFICE LEASE AGREEMENT BETWEEN NORMANDY NICKERSON ROAD, LLC (“LANDLORD”) AND OXFORD IMMUNOTEC, INC. (“TENANT”)Office Lease Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 15th, 2013 Company Industrytelecommunications and furniture and equipment. The Allowance, less a 10% retainage (which retainage shall be payable as part of the final draw upon completion of the Initial Alterations), shall be paid to Tenant or, at Landlord’s option, to the order of the general contractor that performs the Initial Alterations, in periodic disbursements within 30 days after receipt of the following documentation: (i) an application for payment and sworn statement of contractor substantially in the form of AIA Document G-702 covering all work for which disbursement is to be made to a date specified therein; (ii) a certification from an AIA architect substantially in the form of the Architect’s Certificate for Payment which is located on AIA Document G702, Application and Certificate of Payment; (iii) Contractor’s, subcontractor’s and material supplier’s waivers of liens which shall cover all Initial Alterations for which disbursement is being requested and all other statements and forms required for
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. StemCell Technologies, Inc. - and – Oxford...Supply Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledNovember 5th, 2013 Company Industry JurisdictionTHIS AGREEMENT dated as of 31st January, 2008 between OXFORD IMMUNOTEC LTD., a corporation incorporated under the laws of the United Kingdom having its principal place of business in Abingdon, Oxfordshire, United Kingdom (“Oxford”) and STEMCELL TECHNOLOGIES, INC., a corporation incorporated under the laws of British Columbia and Canada having its principal place of business in Vancouver, British Columbia, Canada (“StemCell”).
Dated 21st October 2002 OXFORD IMMUNOTEC GLOBAL PLC (1) and DR P WRIGHTON-SMITH (2) SERVICE AGREEMENTService Agreement • March 27th, 2014 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledMarch 27th, 2014 Company Industry
Officer RESTRICTED SHARE AWARD CERTIFICATE granted under Appendix B to the Oxford Immunotec Global PLCOxford Immunotec Global PLC • March 6th, 2014 • In vitro & in vivo diagnostic substances
Company FiledMarch 6th, 2014 IndustryThis agreement (the “Agreement”) evidences an award of Restricted Shares granted by Oxford Immunotec Global PLC (the “Company”) to the undersigned (the “Grantee”) pursuant to the Company’s 2013 Share Incentive Plan and Appendix B thereto (together, as amended from time to time, the “Plan”).
OXFORD IMMUNOTEC LIMITED NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN FOR NON-CALIFORNIA OPTION HOLDERSNonstatutory Stock Option Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • California
Contract Type FiledOctober 15th, 2013 Company Industry JurisdictionOXFORD IMMUNOTEC LIMITED (reg. no. 4516079) whose registered office is at 115D Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ (the “Company”); and
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Letter of Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 15th, 2013 Company IndustryOxford lmmunotec Limited (“OI”), a company registered in England (number 4516079), whose registered office is at 3 Worcester Street, Oxford, OX1 2PZ.
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SUPPLY AND RESELLER AGREEMENTSupply and Reseller Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
Contract Type FiledOctober 15th, 2013 Company Industry JurisdictionThis Supply and Reseller Agreement (the “AGREEMENT”) is by and between LIFE TECHNOLOGIES CORPORATION (“LTC”), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford Immunotec, Ltd. (“OI”), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, U.K., and is effective as of August 12, 2013 (the “EFFECTIVE DATE”).
ContractAmendment • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 15th, 2013 Company IndustryThis Amendment (the “Second Amendment”) is made as of May 24th, 2011 by and between Mabtech AB, whose registered office is at Augustendalsvägen 19, SE-131 28, Nacka Strand, Sweden, hereinafter referred to as “Seller” or “Mabtech” and Oxford lmmunotec Limited, whose registered office is at 94C Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK, hereinafter referred to as “Buyer” or “OI”.
DEED OF INDEMNITYOxford Immunotec Global PLC • November 8th, 2013 • In vitro & in vivo diagnostic substances • England and Wales
Company FiledNovember 8th, 2013 Industry Jurisdiction
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Marketing Authorization Holder AgreementMarketing Authorization Holder Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledNovember 5th, 2013 Company IndustryThis is an agreement (the “Agreement”) made on and effective as of July 29, 2011 by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8560, Japan (hereinafter referred to as “MAH”).
REGISTRATION RIGHTS AGREEMENT dated 21 November, 2013 by and among Oxford Immunotec Global PLC and certain shareholdersRegistration Rights Agreement • March 27th, 2014 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • New York
Contract Type FiledMarch 27th, 2014 Company Industry Jurisdiction
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • Massachusetts
Contract Type FiledOctober 15th, 2013 Company Industry JurisdictionThis Amended and Restated Employment Agreement (the “Agreement”) is made and entered into effective as of this 1st day of October, 2013 (the “Effective Date”) by and between Oxford Immunotec, Inc., a Delaware corporation with a usual place of business at 700 Nickerson Road, Suite 200, Marlborough, MA 01752 (the “Company”) and Jeff R. Schroeder (the “Employee”).
Officer STOCK OPTION AWARD granted under Appendix B to the Oxford Immunotec Global PLCShare Incentive Plan • March 6th, 2014 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledMarch 6th, 2014 Company IndustryThis agreement (this “Agreement”) evidences a stock option granted by Oxford Immunotec Global PLC (the “Company”) to the undersigned (the “Optionee”) pursuant to the Company’s 2013 Share Incentive Plan and Appendix B thereto (together, as amended from time to time, the “Plan”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENTOxford Immunotec Global PLC • October 15th, 2013 • In vitro & in vivo diagnostic substances
Company FiledOctober 15th, 2013 IndustryThis amendment (the “Amendment”) is entered into and effective as of 22nd December 2011 to a Distributorship Agreement (the “Original Agreement”) dated 5 June 2009 by and among Oxford Immunotec Limited, an English company having offices at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom, Shanghai Fosun Long March Medical Science Co. Ltd., whose registered office and principal place of business is both at 995 Xiang Yin Road, Shanghai, China 200433 and Shanghai Xin Chang Medical Device Co. Ltd., whose registered office is at Room 214, Suite 1, 1128 Ping Liang Road, Shanghai, China 200433.
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO MARKETING AUTHORIZATION HOLDER...Marketing Authorization Holder Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledNovember 5th, 2013 Company IndustryThis Amendment (“Amendment 1”) is made this 1st day of September, 2013, by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8500. Japan (hereinafter referred to as “MAH”)
STANDARD COMMERCIAL LEASELease Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 15th, 2013 Company Industry
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND RESTATED AMENDMENT TO SUPPLY AGREEMENTSupply Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 15th, 2013 Company IndustryThis amended and restated amendment (the “Amendment”) is made and effective as of October 26, 2011 by and between STEMCELL Technologies, having a place of business at 570 West 7th Avenue, Suite 400, Vancouver, British Columbia, Canada, V5Z 1B3 and Oxford Immunotec Ltd., having its principal place of business at 94C Milton Park Abingdon, Oxfordshire, United Kingdom, OX14 4RY.
OXFORD IMMUNOTEC LIMITED INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN FOR NON-CALIFORNIA OPTION HOLDERSIncentive Stock Option Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • California
Contract Type FiledOctober 15th, 2013 Company Industry JurisdictionOXFORD IMMUNOTEC LIMITED (reg. no. 4516079) whose registered office is at 115D Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ (the “Company”); and
OXFORD IMMUNOTEC LIMITED ENTERPRISE MANAGEMENT INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER THE AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN FOR UK QUALIFYING EMPLOYEESEnterprise Management Incentive Stock Option Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • Oxfordshire
Contract Type FiledOctober 15th, 2013 Company Industry JurisdictionOXFORD IMMUNOTEC LIMITED (reg. no. 4516079) whose registered office is at 115D Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ (the “Company”); and , an employee of the Company (the “Option Holder”) on , (the “Date of Grant”)
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Dated: 5 June 2009 OXFORD IMMUNOTEC LIMITED and...Agreement • October 15th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 15th, 2013 Company Industry
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIRST AMENDMENT TO DISTRIBUTORSHIP AGREEMENTDistributorship Agreement • August 4th, 2015 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledAugust 4th, 2015 Company IndustryTHIS FIRST AMENDMENT to Distributorship Agreement (“Amendment”) is made this 22nd day of April, 2015 by and between Oxford Immunotec Limited, a company incorporated in England with number 04516079, whose registered office is at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire OX154 4RZ (the “Company”) and Fosun Long March Medical Science Co. Ltd., (registration number Shanghai Joint-Venture 000422) whose registered office and principal place of business is both at 830 Cheng Yin Road, Shanghai, China 200444 (“Fosun Shanghai I) and Shanghai Xin Chang Medical Device Co. Ltd (registration number 310110000477786), whose registered office and principal place of business is at number 830 Cheng Yin Road, Shanghai, China 200444 (“Fosun Shanghai II”) (Fosun Shanghai I and Fosun Shanghai II are herein collectively referred to as “Distributors”.)
Deed of Novation of Agreement for ServicesOxford Immunotec Global PLC • November 8th, 2013 • In vitro & in vivo diagnostic substances • England and Wales
Company FiledNovember 8th, 2013 Industry JurisdictionThis Deed of Novation of Agreement for Services is made this 8th day of November, 2013, by and between, Oxford Immunotec Limited, a company registered in England and Wales under number 4516079 (“Limited”), Oxford Immunotec Global PLC, a company registered in England and Wales under number 8654254 (“Global”), and Peter Wrighton-Smith, Ph.D., an individual residing at Pippins, Cox Lane, Stanton St. John, Oxfordshire OX33 1HW (“Dr Wrighton-Smith”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • October 25th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledOctober 25th, 2013 Company IndustryTHIS AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT is entered into as of 22 December, 2009 (the “Amended and Restated Agreement”), between Oxford Immunotec Ltd (“OXFORD”), having its registered office at 94C Milton Park, Abingdon, Oxfordshire, OX14 4RY, United Kingdom and Statens Serum Institut (“SSI”), a governmental enterprise under the laws of the Kingdom of Denmark, with offices at 5, Artillerivej, 2300 Copenhagen S, Denmark.
ContractEscrow Agreement • February 27th, 2018 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledFebruary 27th, 2018 Company IndustryTHIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Purchase Agreement between Imugen, Inc. and Oxford Immunotec, Inc. Dated as of June 23, 2016Purchase Agreement • July 6th, 2016 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • Massachusetts
Contract Type FiledJuly 6th, 2016 Company Industry JurisdictionWHEREAS, Seller desires to sell, directly or indirectly, and Purchaser desires to purchase, directly or indirectly, on the terms and subject to the conditions set forth in this Agreement, the Business Assets;
ContractDistributorship Agreement • March 1st, 2017 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledMarch 1st, 2017 Company IndustryTHIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
DEED OF INDEMNITYOxford Immunotec Global PLC • November 8th, 2013 • In vitro & in vivo diagnostic substances • England and Wales
Company FiledNovember 8th, 2013 Industry Jurisdiction